Intel's $20B Equity Raise Completed: Balance Sheet Bolstered, But Dilution Confirms External Funding Dependence

What happened

Intel has completed its $20 billion common stock offering, with proceeds earmarked for capital expenditures and working capital. The company and some coverage frame the raise as a balance-sheet strengthening that enables 'calculated bets' on emerging technologies and long-term value creation. The latest DeepValue master report had already flagged the offering as evidence that internal cash generation and liquidity were insufficient for the planned capex path. Q2 2026 financials show Intel Products recovering with DCAI revenue up 59% YoY, but Intel Foundry still lost $2.1 billion with external revenue of only $293 million. The completed raise locks in dilution above the already inflated share count and leaves the foundry thesis dependent on significant external customer proof by 1H27.

Implication

Investors should treat the equity raise as confirmation that Intel cannot self-fund its foundry strategy and will rely on external capital if foundry losses persist. The master report's base case values the stock at $100, but only if external foundry revenue scales well beyond the current $293 million quarterly run-rate and 14A secures a significant customer. At $97.7, the market is already pricing in a successful AI-driven CPU recovery and a credible foundry rerating, which the 10-K's own language about possibly pausing 14A without a customer contradicts. The next 90 days bring two critical tests: Q3 2026 results (guidance $15.8B-$16.8B revenue, 42% gross margin) and the October 14A PDK 0.9 milestone. Until those confirmations arrive, the risk/reward is asymmetric to the downside, and any further equity-linked funding would signal a broken per-share thesis.

Thesis delta

The completed $20 billion equity raise confirms the funding gap that the master report already flagged. It reinforces the risks of dilution and signals that management expects capex to outpace internally generated cash, so the valuation premium on the foundry thesis remains unjustified. The stance stays WAIT, with conviction unchanged.